Choon-Peng Ng, ImmunoScape CEO

TCR up­start gets fresh fund­ing as it looks to charge to­ward the clin­ic

While sev­er­al com­pa­nies have been find­ing suc­cess in the TCR-T cell ther­a­py space — with In­tel­lia hav­ing its treat­ment ac­cept­ed by the FDA last year — an­oth­er com­pa­ny is us­ing ma­chine learn­ing to get in on the ac­tion and find a can­di­date to bring to­ward the clin­ic.

Im­munoScape, a biotech based in Sin­ga­pore and Cal­i­for­nia, has raised $14 mil­lion in a fresh round of fi­nanc­ing. The com­pa­ny it­self was found­ed in 2016 as a spin­out from the Sin­ga­pore-based Agency for Sci­ence, Tech­nol­o­gy and Re­search, set­ting up its US op­er­a­tions in San Diego in 2020.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

San Diego, CA, USA